Lu-Psma-617 Deployment And Future Of Prostate Cancer Treatment

Lu-PSMA-617 deployment and future of prostate cancer treatment

177Lu-PSMA-617 for the early treatment of prostate cancer

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC

VISION: Lu-177-PSMA-617 in mCRPC

177Lu-PSMA-617 for prostate cancer: TheraP, VISION, UpFrontPSMA and LuTectomy

LuPARP: 177Lu-PSMA-617 and PARP inhibitor combination for prostate cancer

Real-world outcomes of 177Lu-PSMA-617 in mCRPC

VISION: tolerability of 177Lu-PSMA-617 by treatment exposure in patients with mCRPC

Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRI

Prostate Cancer Research Institute

PSMA Targeting for Treatment of Advanced Prostate Cancer - 2021 Prostate Cancer Patient Conference

University of California Television (UCTV)

Predicting 177Lu-PSMA-617 in men with prostate cancer with nomograms

PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer

Lu-PSMA Radioligand Therapy

University of California Television (UCTV)

Radioligands in the future of prostate cancer treatment

VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC

TheraP Trial and Effectiveness of Lu-PSMA-617

Grand Rounds in Urology

Dr. Gafita on Sequencing 177Lu-PSMA-617 in mCRPC

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prosta...

Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study

European Society for Medical Oncology (ESMO)

177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)